The Wealth Illusion: Why America’s Richest Die Like Europe’s Poorest

P.S. Wilson Healthcare
Mar 16
3 min read

In the United States, we have long operated under the assumption that wealth is the ultimate shield against health-related risk. We believe that if you have the resources, you can buy your way into superior outcomes, elite longevity, and peak performance. However, a groundbreaking 2025 study published in the New England Journal of Medicine (NEJM) has shattered this myth, revealing a systemic failure in the American health architecture that even the highest levels of wealth cannot overcome.

The data is startling: The wealthiest Americans now face mortality rates comparable to the poorest individuals in Northern and Western Europe. Despite spending nearly twice as much on healthcare as any other comparable nation—reaching a staggering $4.9 trillion or $14,570 per capita in 2023—the U.S. continues to deliver inferior survival outcomes across every wealth decile. At P.S. Wilson Healthcare, we view this not as a medical failure, but as a Performance Risk Governance crisis.

The Survival Gap: Wealth is No Longer a Shield

For decades, the "wealth-health gradient" was a reliable predictor of longevity. While wealth still provides a relative advantage within the U.S., it no longer provides a global advantage. The NEJM study found that the wealthiest group in Northern and Western Europe had mortality rates approximately 35% lower than the wealthiest group in the United States .

This means that an American executive in the top 1% of earners is essentially operating with the same health-related risk profile as a low-income citizen in a well-governed European state. This is a profound realization for high-performing professionals who assume their "platinum" insurance and executive physicals are providing a competitive edge. In reality, they are navigating a high-cost, low-efficiency system that fails to protect their most valuable asset: their long-term capacity.

Comparative Health Performance: U.S. vs. Europe (2025 Data)

Metric	United States	Northern/Western Europe	The Performance Gap
Healthcare Spending (Per Capita)	~$14,570	~$6,000 - $8,000	U.S. spends ~2x more
Mortality (Wealthiest Decile)	Baseline	35% Lower than U.S.	U.S. Wealth is inefficient
Survival Odds (Wealthiest U.S.)	Comparable to Poorest Europe	N/A	Systemic Risk Exposure
Primary Focus	Reactive Intervention	Preventive Governance	Architecture Failure

The Cost of Inefficiency: A Governance Failure

Why does the U.S. spend more to achieve less? The answer lies in the difference between Healthcare and Health Governance. The American system is engineered for high-intensity, reactive intervention—treating disease after it has already eroded an individual's capacity. In contrast, Northern and Western European systems are built on a foundation of preventive governance and systemic stability.

For the high-performing professional, this "spending gap" represents a massive unhedged risk. You are paying a premium for a system that is not designed to optimize your performance or safeguard your longevity. Other countries publish this data routinely; in the U.S., we tend to ignore it in favor of the latest medical "breakthroughs." But as the NEJM data shows, breakthroughs in treatment cannot compensate for a breakdown in architecture.

The P.S. Wilson Perspective: Health as a Strategic Asset

At P.S. Wilson Healthcare, we don't accept the "inevitable erosion" that the U.S. system currently facilitates. Our Health-First Framework™ is designed to bypass the inefficiencies of the broader healthcare market by treating health as a Strategic Performance Asset.

We recognize that for an executive, health is a variable that must be governed with the same rigor as financial or operational risk. If the wealthiest Americans are dying at the same rate as the poorest Europeans, it is because they are lacking the Performance Risk Governance Architecture that ensures sustained capacity.

•Beyond Reactive Care: We move past the "wait and treat" model that defines the U.S. system.

•Measurable Standards: We convert health data into executable performance standards.

•Risk Mitigation: We identify hidden health-related risk exposure before it impacts decision quality or enterprise value.

Conclusion: Reclaiming Your Competitive Edge

The 2025 NEJM study is a wake-up call for every leader who believes their wealth has secured their health. The data is clear: the system you are operating in is fundamentally flawed, and your wealth is not buying you the protection you think it is.

To achieve true longevity and sustained high performance, you must look beyond the standard American healthcare model. You must adopt a Health-First approach that prioritizes governance over intervention and capacity over cost. In a world where the wealthiest are no longer the healthiest, the only true competitive advantage is a structured, evidence-informed system that protects your most critical asset.